TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TAK - US8740602052 - ADR
14.9 USD
+0.07 (+0.47%)
14.9 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to TAK. TAK was compared to 192 industry peers in the Pharmaceuticals industry. TAK has an excellent profitability rating, but there are concerns on its financial health. TAK is not valued too expensively and it also shows a decent growth rate. TAK also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
TAK had positive earnings in the past year.
In the past year TAK had a positive cash flow from operations.
Each year in the past 5 years TAK has been profitable.
TAK had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
TAK has a Return On Assets of 0.23%. This is in the better half of the industry: TAK outperforms 77.60% of its industry peers.
The Return On Equity of TAK (0.46%) is better than 79.17% of its industry peers.
TAK has a better Return On Invested Capital (1.87%) than 79.17% of its industry peers.
The Average Return On Invested Capital over the past 3 years for TAK is significantly below the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROIC | 1.87% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
1.3 Margins
The Profit Margin of TAK (0.75%) is better than 77.60% of its industry peers.
TAK's Profit Margin has improved in the last couple of years.
The Operating Margin of TAK (8.46%) is better than 80.21% of its industry peers.
TAK's Operating Margin has improved in the last couple of years.
With a decent Gross Margin value of 64.60%, TAK is doing good in the industry, outperforming 73.44% of the companies in the same industry.
TAK's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% |
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TAK is creating some value.
Compared to 1 year ago, TAK has more shares outstanding
Compared to 5 years ago, TAK has more shares outstanding
TAK has a better debt/assets ratio than last year.
2.2 Solvency
TAK has an Altman-Z score of 1.17. This is a bad value and indicates that TAK is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TAK (1.17) is comparable to the rest of the industry.
TAK has a debt to FCF ratio of 5.04. This is a neutral value as TAK would need 5.04 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 5.04, TAK belongs to the best of the industry, outperforming 82.81% of the companies in the same industry.
A Debt/Equity ratio of 0.61 indicates that TAK is somewhat dependend on debt financing.
TAK has a worse Debt to Equity ratio (0.61) than 68.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Altman-Z | 1.17 |
ROIC/WACC1.16
WACC1.61%
2.3 Liquidity
A Current Ratio of 1.36 indicates that TAK should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.36, TAK is doing worse than 73.44% of the companies in the same industry.
TAK has a Quick Ratio of 1.36. This is a bad value and indicates that TAK is not financially healthy enough and could expect problems in meeting its short term obligations.
TAK's Quick ratio of 0.76 is on the low side compared to the rest of the industry. TAK is outperformed by 84.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 |
3. Growth
3.1 Past
The earnings per share for TAK have decreased strongly by -88.38% in the last year.
Measured over the past years, TAK shows a quite strong growth in Earnings Per Share. The EPS has been growing by 19.20% on average per year.
TAK shows a decrease in Revenue. In the last year, the revenue decreased by -2.84%.
Measured over the past years, TAK shows a small growth in Revenue. The Revenue has been growing by 6.84% on average per year.
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
3.2 Future
TAK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 46.55% yearly.
Based on estimates for the next years, TAK will show a small growth in Revenue. The Revenue will grow by 0.19% on average per year.
EPS Next Y96.76%
EPS Next 2Y70.53%
EPS Next 3Y46.55%
EPS Next 5YN/A
Revenue Next Year-1.53%
Revenue Next 2Y-0.48%
Revenue Next 3Y0.19%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
TAK is valuated quite expensively with a Price/Earnings ratio of 212.86.
Based on the Price/Earnings ratio, TAK is valued a bit cheaper than 76.04% of the companies in the same industry.
TAK's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.39.
The Price/Forward Earnings ratio is 23.60, which indicates a rather expensive current valuation of TAK.
75.00% of the companies in the same industry are more expensive than TAK, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of TAK to the average of the S&P500 Index (23.84), we can say TAK is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 212.86 | ||
| Fwd PE | 23.6 |
4.2 Price Multiples
TAK's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TAK is cheaper than 87.50% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, TAK is valued cheaply inside the industry as 93.75% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.02 | ||
| EV/EBITDA | 10.07 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of TAK may justify a higher PE ratio.
TAK's earnings are expected to grow with 46.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.2
PEG (5Y)11.09
EPS Next 2Y70.53%
EPS Next 3Y46.55%
5. Dividend
5.1 Amount
TAK has a Yearly Dividend Yield of 4.46%, which is a nice return.
Compared to an average industry Dividend Yield of 0.45, TAK pays a better dividend. On top of this TAK pays more dividend than 96.35% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 1.87, TAK pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.46% |
5.2 History
The dividend of TAK has a limited annual growth rate of 1.18%.
TAK has been paying a dividend for at least 10 years, so it has a reliable track record.
TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
935.06% of the earnings are spent on dividend by TAK. This is not a sustainable payout ratio.
TAK's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP935.06%
EPS Next 2Y70.53%
EPS Next 3Y46.55%
14.9
+0.07 (+0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners46.91%
Inst Owner Change8.68%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap47.07B
Revenue(TTM)4.42T
Net Income(TTM)33.08B
Analysts73.68
Price Target16.25 (9.06%)
Short Float %0.36%
Short Ratio4.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.46% |
Yearly Dividend0.61
Dividend Growth(5Y)1.18%
DP935.06%
Div Incr Years2
Div Non Decr Years3
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-41.49%
Min EPS beat(2)-121.92%
Max EPS beat(2)38.94%
EPS beat(4)1
Avg EPS beat(4)-35.42%
Min EPS beat(4)-121.92%
Max EPS beat(4)38.94%
EPS beat(8)4
Avg EPS beat(8)-31.47%
EPS beat(12)6
Avg EPS beat(12)-33.69%
EPS beat(16)7
Avg EPS beat(16)-40.61%
Revenue beat(2)0
Avg Revenue beat(2)-6.4%
Min Revenue beat(2)-6.76%
Max Revenue beat(2)-6.04%
Revenue beat(4)0
Avg Revenue beat(4)-3.84%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)-0.48%
Revenue beat(8)4
Avg Revenue beat(8)3.03%
Revenue beat(12)7
Avg Revenue beat(12)3.44%
Revenue beat(16)11
Avg Revenue beat(16)3.69%
PT rev (1m)-2.56%
PT rev (3m)-7.92%
EPS NQ rev (1m)15.75%
EPS NQ rev (3m)28.76%
EPS NY rev (1m)-7.36%
EPS NY rev (3m)-11.74%
Revenue NQ rev (1m)1.73%
Revenue NQ rev (3m)1.7%
Revenue NY rev (1m)-0.31%
Revenue NY rev (3m)-0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 212.86 | ||
| Fwd PE | 23.6 | ||
| P/S | 1.68 | ||
| P/FCF | 8.02 | ||
| P/OCF | 6.17 | ||
| P/B | 1.04 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.07 |
EPS(TTM)0.07
EY0.47%
EPS(NY)0.63
Fwd EY4.24%
FCF(TTM)1.86
FCFY12.46%
OCF(TTM)2.41
OCFY16.21%
SpS8.89
BVpS14.36
TBVpS-3.22
PEG (NY)2.2
PEG (5Y)11.09
Graham Number4.75
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROCE | 3.03% | ||
| ROIC | 1.87% | ||
| ROICexc | 1.99% | ||
| ROICexgc | 8.07% | ||
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% | ||
| FCFM | 20.88% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
ROICexc(3y)2.76%
ROICexc(5y)2.73%
ROICexgc(3y)14.61%
ROICexgc(5y)14.15%
ROCE(3y)4.25%
ROCE(5y)4.14%
ROICexgc growth 3Y-6.2%
ROICexgc growth 5Y8.09%
ROICexc growth 3Y-3.88%
ROICexc growth 5Y10.72%
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Debt/EBITDA | 3.9 | ||
| Cap/Depr | 37.3% | ||
| Cap/Sales | 6.28% | ||
| Interest Coverage | 3.04 | ||
| Cash Conversion | 107.4% | ||
| Profit Quality | 2788.5% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 | ||
| Altman-Z | 1.17 |
F-Score6
WACC1.61%
ROIC/WACC1.16
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
EPS Next Y96.76%
EPS Next 2Y70.53%
EPS Next 3Y46.55%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
Revenue Next Year-1.53%
Revenue Next 2Y-0.48%
Revenue Next 3Y0.19%
Revenue Next 5YN/A
EBIT growth 1Y-31.07%
EBIT growth 3Y-0.52%
EBIT growth 5Y13.39%
EBIT Next Year435.35%
EBIT Next 3Y77.31%
EBIT Next 5YN/A
FCF growth 1Y613.62%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y24.54%
OCF growth 3Y-2%
OCF growth 5Y9.54%
TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ
What is the ChartMill fundamental rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
ChartMill assigns a fundamental rating of 5 / 10 to TAK.
What is the valuation status of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
ChartMill assigns a valuation rating of 5 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.
What is the profitability of TAK stock?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 7 / 10.
Can you provide the expected EPS growth for TAK stock?
The Earnings per Share (EPS) of TAKEDA PHARMACEUTIC-SP ADR (TAK) is expected to grow by 96.76% in the next year.
How sustainable is the dividend of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
The dividend rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 7 / 10 and the dividend payout ratio is 935.06%.